<DOC>
	<DOC>NCT01696461</DOC>
	<brief_summary>This is a Phase II, open-label, two strata, multicenter, prospective study of plerixafor-mobilized HLA-identical sibling allografts in recipients with hematological malignancies. This study will establish the safety and efficacy of subcutaneous plerixafor for this purpose.</brief_summary>
	<brief_title>A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<criteria>Donor: Donor eligibility will be determined according to applicable federal, state and local regulations and institutional standards 1865 years of age 6/6 HLAmatched sibling Fulfill individual Transplant Center criteria to serve as a mobilized blood cell donor Serum creatinine &lt;2.0mg/dl Recipient: 18 to 65 years of age 6/6 HLA antigen matched sibling willing to donate PBSC for transplant Fulfill individual Transplant Center Criteria for transplant One of the following diagnoses: Acute myelogenous leukemia (AML) in 1st remission or beyond with &lt;5% marrow blasts and no circulating blasts. Marrow must be done within 30 days of the start of transplant conditioning regimen in alignment with other pretransplant assessments. Acute lymphoblastic leukemia (ALL) in 1st remission or beyond with &lt;5% marrow blasts and no circulating blasts Myelodysplastic syndrome, either intermediate1,2, or high risk by International Prognostic Scoring System or transfusion dependent Chronic myelogenous leukemia (CML) failing or intolerant to tyrosine kinase inhibitor based therapy NonHodgkin's lymphoma (NHL) or Hodgkin's disease (HD) in 2nd or greater complete remission, partial remission, or in relapse (but with at least stable disease after most recent therapy) Chronic lymphocytic leukemia (CLL), relapsing after at least one prior regimen, or in remission with 17p deletion Serum creatinine must be &lt;2.0mg/dl Total bilirubin and AST &lt;3x normal Infectious disease marker (IDM) monitoring will be performed per institutional standards Karnofsky performance status of 70% or greater. Patients who have undergone a prior autologous transplantation are eligible for a reduced intensity transplant only Donor: Donor unwilling or unable to give informed consent, or unable to comply with the protocol including required followup and testing Donor already enrolled on another investigational agent study Pregnant or breast feeding females, or females not willing or able to use adequate contraception if sexually active Recipient: Patient unwilling or unable to give informed consent, or unable to comply with the protocol including required followup and testing Patients with active, uncontrolled infection at the time of the transplant preparative regimen Pregnant or breast feeding females, or females not willing or able to use adequate contraception if sexually active Patients with a history of previous CNS tumor involvement showing active symptoms or signs along with documented disease on lumbar puncture and MRI of the brain within 30 days of start of conditioning A condition, which, in the opinion of the clinical investigator, would interfere with the evaluation of primary and secondary endpoints.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>